BIND Therapeutics Promotes Key Executives: Organization Positioned For Continued Growth
3/4/2014 7:20:52 AM
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team. Andrew Hirsch has been appointed Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND’s Russian operations.
Help employers find you! Check out all the jobs and post your resume.
comments powered by